HomePHIO • NASDAQ
add
Phio Pharmaceuticals Corp
Nakaraang pagsara
$1.07
Sakop ng araw
$1.05 - $1.13
Sakop ng taon
$0.97 - $9.79
Market cap
11.84M USD
Average na Volume
539.21K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Sa balita
Mga Financial
Income Statement
Kita
Net na kita
| (USD) | Set 2025info | Y/Y na pagbabago |
|---|---|---|
Kita | — | — |
Gastos sa pagpapatakbo | 1.32M | 39.96% |
Net na kita | -2.39M | -56.96% |
Net profit margin | — | — |
Kita sa bawat share | -0.44 | — |
EBITDA | -2.50M | -57.51% |
Aktuwal na % ng binabayarang buwis | — | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (USD) | Set 2025info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 10.70M | 98.61% |
Kabuuang asset | 11.50M | 96.16% |
Kabuuang sagutin | 1.67M | 81.28% |
Kabuuang equity | 9.84M | — |
Natitirang share | 10.76M | — |
Presyo para makapag-book | 0.63 | — |
Return on assets | -54.92% | — |
Return on capital | -62.83% | — |
Cash Flow
Net change in cash
| (USD) | Set 2025info | Y/Y na pagbabago |
|---|---|---|
Net na kita | -2.39M | -56.96% |
Cash mula sa mga operasyon | -2.08M | -6.76% |
Cash mula sa pag-invest | -7.00K | — |
Cash mula sa financing | 2.02M | -23.55% |
Net change in cash | -70.00K | -110.12% |
Malayang cash flow | -1.27M | 11.16% |
Tungkol
Phio Pharmaceuticals Corporation is a US clinical stage biotechnology company developing its INTASYL siRNA in immuno-oncology. Formerly known as RXi Pharmaceuticals, the company's name was changed to Phio Pharmaceuticals in 2018. Wikipedia
Itinatag
2011
Website
Mga Empleyado
5
